Litcius/Paper detail

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljević, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Yvonne A. Efebera, Matthew Faiman, Alfred L. Garfall, Kelly Godby, Jens Hillengaß, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Malin Hultcrantz, Sarah Larson, Michaela Liedtke, Thomas G. Martin, James Omel, Kenneth H. Shain, Douglas W. Sborov, Keith Stockerl‐Goldstein, Donna Weber, Jennifer Keller, Rashmi Kumar

2020Journal of the National Comprehensive Cancer Network277 citationsDOI

Abstract

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.

Topics & Concepts

MedicineMultiple myelomaBone marrowPlasmacytomaClinical PracticeInternal medicineOncologyPlasma cell neoplasmFamily medicineMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsCancer Treatment and Pharmacology
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology | Litcius